COX enzymes convert arachidonic acid, a fatty acid embedded in cell membranes, into prostaglandins — a family of chemical messengers that regulate inflammation, pain signaling, blood clotting, stomach protection, kidney function, and much more. These enzymes are the target of aspirin, ibuprofen, naproxen, and an entire class of prescription anti-inflammatory drugs, which makes understanding them relevant to anyone who has ever reached for a pain reliever. The two main forms, COX-1 and COX-2, have distinct but overlapping roles, and the real biology behind them is messier and more interesting than the tidy textbook version suggests.
What COX Enzymes Do
The cyclooxygenase enzyme system is the major pathway catalyzing the conversion of arachidonic acid into prostaglandins.1PubMed Central. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney Prostaglandins are not one substance. They are a family of short-lived molecules, including thromboxane and prostacyclin, that act locally to widen or narrow blood vessels, sensitize nerve endings to pain, recruit immune cells, shield the stomach lining from acid, and regulate blood flow in the kidneys. Both COX-1 and COX-2 convert the same starting material (arachidonic acid) into the same initial intermediate, which is then turned into different prostaglandins depending on the tissue.2The Journal of Immunology. Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-2
The “Housekeeping” vs “Inflammatory” Split Is Too Simple
For years, the standard teaching was tidy: COX-1 handles everyday housekeeping functions like stomach protection and platelet maintenance, while COX-2 is switched on only when inflammation strikes. This framing drove the development of selective COX-2 inhibitors in the 1990s, under the logic that blocking COX-2 alone would stop inflammation without causing stomach ulcers.
The real picture is more complicated. A detailed study of COX distribution in healthy human tissues found COX-1 in blood vessels, smooth muscle cells, platelets, and mesothelial cells, while COX-2 appeared predominantly in the working cells of many organs, with few exceptions like the heart. The researchers concluded that the distribution of COX isoforms is “much more complex than generally believed.”3PubMed Central. Cyclooxygenase in normal human tissues–is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? Separately, COX-2 has been shown to be constitutively expressed, with no overt inflammation required, in the kidney, gastrointestinal tract, brain, and thymus.4PubMed Central. Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-κB and NFAT transcriptional pathways This matters because drugs aimed at COX-2 don’t just suppress inflammation — they also interfere with normal housekeeping in those organs, which helps explain side effects like blood pressure elevation and kidney stress.
Pain Signaling and How NSAIDs Interrupt It
When tissue is injured, cells release arachidonic acid, COX-2 expression ramps up, and prostaglandin levels surge. One prostaglandin in particular, PGE2, sensitizes pain-sensing nerve endings so they fire more easily. This is why inflamed tissue hurts more than it otherwise would — prostaglandins lower the threshold at which nerves send pain signals. Blocking COX-2 with a selective inhibitor can prevent or shorten this sensitization of nerve endings.5PubMed. Peripheral prostaglandin E2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors That is the core mechanism behind anti-inflammatory pain relief: you are not numbing the nerve itself, you are removing the chemical that makes it hypersensitive.
Protecting the Stomach Lining
Prostaglandins produced by COX enzymes play a critical role in the stomach’s ability to defend itself against its own acid. They stimulate mucus and bicarbonate secretion, maintain blood flow to the stomach wall, and promote cell turnover. When you take an NSAID that blocks COX-1, you cut off this protective prostaglandin supply. With chronic use, the development of stomach ulcers becomes a genuine clinical concern.6PubMed. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? The relationship is well established: prostaglandin deficiency in the stomach lining increases vulnerability to ulcer formation, and giving supplemental prostaglandins reduces ulcer risk.7Gastroenterology Clinics of North America. COX Enzymes: Central to Inflammation, Pain, and Cardiovascular Health This is the fundamental trade-off of traditional NSAIDs: they relieve pain by blocking COX, but they compromise the stomach’s defenses in the process.
The Cardiovascular Balancing Act
COX enzymes produce two substances with opposing effects on blood vessels and platelets. Thromboxane A2, made primarily through COX-1 in platelets, promotes clotting and constricts blood vessels. Prostacyclin, produced largely through COX-2 in the cells lining blood vessels, does the opposite: it relaxes vessels and discourages clotting. In mouse studies, knocking out the prostacyclin receptor enhanced platelet activation and vascular proliferation after injury, while knocking out the thromboxane receptor dampened those responses. Eliminating both receptors cancelled the effect out.8PubMed. Role of prostacyclin in the cardiovascular response to thromboxane A2 Prostacyclin, in other words, acts as a natural brake on thromboxane’s clot-promoting action.
In endothelial cells, COX-2 induction is associated with a roughly 54-fold increase in prostacyclin synthesis, while thromboxane production barely changes.2The Journal of Immunology. Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-2 So a drug that selectively blocks COX-2 but leaves COX-1 alone suppresses prostacyclin without touching thromboxane. That tilts the balance toward clotting and vessel constriction, which is the mechanism most widely invoked to explain why some selective COX-2 inhibitors raised heart attack risk.
Why Rofecoxib Was Pulled and What Happened Next
The selective COX-2 inhibitor rofecoxib (Vioxx) was withdrawn in 2004 after trial data revealed it roughly doubled the risk of heart attack. A large network analysis of NSAID cardiovascular safety confirmed that rofecoxib carried the highest myocardial infarction risk among the drugs studied, with a rate ratio of about 2.1 compared to placebo. Diclofenac and etoricoxib had the highest risk of cardiovascular death, while naproxen appeared the least harmful overall.9BMJ. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Whether COX-2 selectivity itself is the problem, or whether rofecoxib had unique pharmacological properties, remained contentious. Preclinical work found that COX-2 inhibitors as a class did not affect platelet aggregation, blood pressure, or endothelial cell activation in lab models, but rofecoxib uniquely caused an endothelium-dependent constriction response in arterial preparations. The authors concluded that rofecoxib’s cardiovascular events may not be predicted by COX-2 potency or selectivity alone.10SSRN. Disconnect between COX-2 Selective Inhibition and Cardiovascular Risk in Preclinical Models
The PRECISION trial, which followed over 24,000 arthritis patients, provided some reassurance about celecoxib, the most widely prescribed COX-2 selective inhibitor still on the market. Cardiovascular events occurred in roughly 2.3% of celecoxib users compared with 2.5% for naproxen and 2.7% for ibuprofen, and celecoxib was noninferior to both. It also caused fewer gastrointestinal events than either comparator and fewer kidney problems than ibuprofen.11PubMed. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis The upshot is that the cardiovascular scare of the early 2000s was real but was not evenly distributed across all COX-2 inhibitors.
Kidneys and Blood Pressure
COX-2 has a constant, non-inflammatory job in the kidneys: it helps maintain blood flow, triggers renin release, and regulates sodium excretion.12PubMed. Cyclooxygenases, the kidney, and hypertension Blocking COX-2 can transiently reduce sodium excretion and lead to mild or moderate blood pressure increases. In people who are already dehydrated or have compromised kidney perfusion, as often happens in elderly patients or those with heart failure, interfering with COX-2 can cause a meaningful decline in kidney function.12PubMed. Cyclooxygenases, the kidney, and hypertension
Research on small renal arteries confirms that COX-2, not COX-1, is the isoform controlling their relaxation response.13PubMed Central. Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a Novel PPARβ/δ-Dependent Vasodilator Pathway This is one reason why nephrologists are cautious about long-term NSAID use in patients with kidney disease, regardless of whether the drug is COX-1 selective, COX-2 selective, or nonselective.
Aspirin Is Not Like Other NSAIDs
All traditional NSAIDs inhibit both COX isoforms, but aspirin does something unique: it permanently disables the enzyme by attaching an acetyl group to it. Platelets, which lack a nucleus and cannot manufacture replacement proteins, lose their COX-1 activity for the rest of their lifespan, roughly 7 to 10 days. That is why low-dose aspirin provides sustained anti-clotting protection: a single dose keeps those platelets from producing thromboxane permanently.
This mechanism also creates a drug interaction worth knowing about. Ibuprofen, if taken before aspirin, can physically block aspirin from reaching its binding site on COX-1, weakening aspirin’s antiplatelet effect. Rofecoxib, acetaminophen, and diclofenac did not show this interference.14PubMed. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin For people taking daily low-dose aspirin for heart protection, timing ibuprofen use matters: taking aspirin first and waiting before adding ibuprofen helps preserve the antiplatelet benefit.
Aspirin also triggers an unusual anti-inflammatory pathway. When it acetylates COX-2 without fully shutting the enzyme down, the modified enzyme produces aspirin-triggered lipoxins, molecules that actively help resolve inflammation rather than just suppressing it. When researchers blocked this pathway with a selective COX-2 inhibitor, aspirin’s effect on blood pressure was worsened.15PubMed. Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone This resolution-promoting action is part of why aspirin’s pharmacology is genuinely distinct from other NSAIDs in ways that still surprise researchers.
The Acetaminophen Mystery
Acetaminophen (paracetamol) has been used for decades, yet its mechanism of action remains surprisingly uncertain. The long-standing view held that it had little effect on peripheral prostaglandins. More recent work found that acetaminophen inhibited COX-2 by more than 80% after an oral dose, a degree comparable to prescription anti-inflammatory drugs, while showing roughly 56% COX-1 inhibition.16PubMed. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man That finding, if generalizable, would explain both acetaminophen’s pain-relieving effect and its comparatively gentle profile on the stomach.
However, the picture is not settled. Acetaminophen’s COX-inhibiting ability depends heavily on local conditions: it works well when arachidonic acid and peroxide levels are low but loses potency when they are abundant, such as at sites of active inflammation.17PubMed. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings Some mouse data suggest it may work partly through a COX-1 variant rather than COX-2 alone.18PubMed Central. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action Researchers still argue about which COX form acetaminophen primarily targets and by what molecular interaction, making it one of the most widely consumed drugs whose mechanism remains genuinely open to debate.
COX-2 and Colorectal Cancer
COX-2 plays a role beyond inflammation in certain cancers. In colorectal cancer, COX-2 and its product PGE2 have been closely linked to tumor development and progression.19PubMed Central. The Role of Cyclooxygenase-2 in Colorectal Cancer Tumor cells that overexpress COX-2 produce factors that stimulate the growth of new blood vessels, a process that feeds tumor expansion.20PubMed. Cyclooxygenase regulates angiogenesis induced by colon cancer cells A study of 128 colorectal cancer cases found COX-2 expression in about 68% of tumors, and COX-2-positive tumors had significantly higher blood vessel counts, more frequent metastasis, and were more likely to be advanced stage.21PubMed Central. Cyclooxygenase-2 expression and angiogenesis in colorectal cancer
This connection has driven interest in whether aspirin can prevent colorectal cancer. Multiple large studies support the conclusion that regular low-dose aspirin reduces the long-term risk, particularly in people over 50 who are at elevated cardiovascular risk.22PubMed Central. Colorectal cancer chemoprevention: is aspirin still in the game? – Section: II. Aspirin use to prevent or treat colorectal adenoma or cancer Among people 70 and older, regular aspirin use was associated with about a 20% lower risk, but only if use began before age 70. Starting aspirin at or after 70 did not show the same benefit.23JAMA Oncology. Aspirin Use and Risk of Colorectal Cancer Among Older Adults In people with Lynch syndrome, a hereditary condition that greatly increases colorectal cancer risk, 600 mg of aspirin daily for around two years cut cancer incidence by roughly 60% over the follow-up period.24The Lancet. Cancellation of aspirin or resistant starch for colorectal neoplasia in the Lynch syndrome
Aspirin-Exacerbated Respiratory Disease
In roughly 7% of adults with asthma, aspirin and other COX-1-blocking NSAIDs trigger severe bronchospasm. The mechanism involves a metabolic shunt: when COX-1 is blocked, the usual prostaglandin pathway stalls and arachidonic acid gets redirected toward the production of cysteinyl leukotrienes, potent molecules that constrict airways and increase mucus production.25PubMed Central. Aspirin-exacerbated asthma Losing PGE2 is part of the problem, since PGE2 normally acts as a brake on leukotriene production.26PubMed. Aspirin-induced asthma: clinical aspects, pathogenesis and management People with this condition can generally tolerate selective COX-2 inhibitors, because those drugs leave COX-1 and its PGE2 output intact. This is one clinical scenario where the distinction between COX isoforms directly determines which medications are safe.
COX in Fertility and Reproduction
COX-2 is essential for several steps in reproduction. In animal models, COX-2 deficiency impairs ovulation, and the prostaglandin PGE2 acting through a specific receptor subtype is required for normal egg release. Interestingly, ovulation in young mice is less dependent on this pathway than in adults, suggesting that reliance on COX-2 for egg release increases with age.27Biology of Reproduction. Diversification of Cyclooxygenase-2-Derived Prostaglandins in Ovulation and Implantation COX-2 inhibitors have been shown to affect ovulation and may impair fertilization, implantation, and the onset of labor.28Fertility and Sterility. The potential danger of COX-2 inhibitors A related prostaglandin, PGF2α, regulates functions including corpus luteum breakdown, maintenance of early pregnancy, and uterine contractions during labor.29PubMed. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation
These findings raise practical concerns. Women trying to conceive are often advised to avoid NSAIDs around the time of ovulation, and COX-2 inhibitors carry explicit warnings about reproductive effects. The reproductive role of COX-2 is one of the clearest examples of the enzyme doing work that has nothing to do with inflammation.
Omega-3 Fats and the COX Pathway
Dietary omega-3 fatty acids, particularly EPA from fish oil, compete with arachidonic acid as a substrate for COX enzymes. When EPA displaces arachidonic acid, the resulting prostaglandins and thromboxanes are structurally different and generally less pro-inflammatory. Studies have observed that increased EPA intake suppresses the production of arachidonic-acid-derived prostaglandins and increases formation of the corresponding EPA-derived mediators.30PubMed Central. The Effect of Omega-3 and Omega-6 Polyunsaturated Fatty Acids on the Production of Cyclooxygenase and Lipoxygenase Metabolites by Human Umbilical Vein Endothelial Cells This substrate-level competition is one plausible mechanism behind the anti-inflammatory reputation of omega-3 supplements, though the clinical significance of this shift varies widely depending on dose and context.
An Ancient Enzyme Family
COX enzymes are not a mammalian invention. Genes encoding COX isoforms have been found in corals, tunicates, and vertebrates, and in every phylum where COX has been identified there are two genes encoding two isoforms.31PubMed Central. The cyclooxygenases The ancestral COX gene appears to have been present in the common ancestor of cnidarians (corals and jellyfish) and bilaterians (most other animals), though it is absent from sponge and ctenophore genomes.32PubMed. Reconstruction of cyclooxygenase evolution in animals suggests variable, lineage-specific duplications, and homologs with low sequence identity Whether the two-isoform pattern arose from a single ancient gene duplication or from multiple independent duplications in different lineages remains an open question.
The structural difference between COX-1 and COX-2 that allows selective drug targeting is remarkably small. A single amino acid swap at one position in the active site — valine in COX-2 versus isoleucine in COX-1 — is enough to determine whether a selective COX-2 inhibitor can bind.33PubMed. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors That a billion-dollar drug class was built on a one-amino-acid difference gives some sense of how finely tuned enzyme pharmacology can be.